Gilead presents new NASH treatment data

Gilead was the first bio-pharmaceutical company to begin major research into NASH related treatments.  They have since been joined by dozens of others attempting to gain a foothold in the space, which is expected to be lucrative based on the percentage of population at risk.

They recently sent Dr. Mani Subramanian, PhD, to speak at the 2018 International Liver Congress, Continue reading “Gilead presents new NASH treatment data”

Let’s Talk About Your Weight

There’s an uncomfortable truth for many individuals to face regarding their health.  Rates of obesity in the USA have increased by an average total of 15% since 1990.  In the majority of states more than 25% of the entire population is obese.  In many more rural states these numbers regularly exceed 35%.  These climbing rates affect a whole host of health issues and have been directly linked to exceptionally slow mortality improvement when compared to other western nations.

America, this is a wake up call.  You’re too fat. Continue reading “Let’s Talk About Your Weight”

What is NASH?

NASH is the acronym for nonalcoholic steatohepatitis.  It’s a type of advanced liver disease that is clinically indistinguishable from alcohol-induced liver damage, but whose causes are totally different.  Late stage NASH leads invariably to chronic cirrhosis and ultimately liver failure and death.  The most common cause of NASH is long-term obesity, and so the threat has grown in relation to the rising rates of obesity in western society.  Therefore NASH is quickly becoming an epidemic, with estimates of 15 to 30 million Americans living with the disease, the vast majority of whom are undiagnosed.  They are living with a ticking time bomb inside their bodies. Continue reading “What is NASH?”